Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals

Friday, January 12, 2018

Ligand Pharmaceuticals Incorporated announces it has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals. Under the license, Glenmark will be able to use the full OmniAb platform including OmniChicken™, OmniRat®, OmniMouse® and OmniFlic® to discover fully human mono- and multispecific antibodies. Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody. Glenmark will be responsible for all costs related to the programs.

“This agreement provides Glenmark access to our transgenic animal technology platform that is the only to include three separate species in a single license. This diversity in species is expected to provide a wider repertoire of therapeutic antibodies than a single-species technology,” said John Higgins, Chief Executive Officer of Ligand. “This is the first new OmniAb partnership to include OmniChicken in addition to OmniRat, OmniMouse and OmniFlic. Ligand’s acquisition of OmniChicken demonstrated its commitment to provide the best antibody-discovery technologies to its current and future partners.”

TOP